Qiang Wei

12PUBLICATIONS
7CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 29, 2026
Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism.

|Mar 26, 2026
SMARCA4 promotes lineage plasticity and enzalutamide resistance in prostate cancer by regulating PROX1 via H3K27 acetylation.

Chenwei Wu, Mayao Luo, Chaojian Wu

|Feb 27, 2026
UHRF1 regulates AR ubiquitination to promote the loss of AR signaling and enzalutamide resistance in progression of prostate cancer.

Yifan Zhang, Zhaojun Yu, Yadong Li

|Nov 17, 2025
Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progression.

Haoran Wen, Maierhaba Maheremu, Kaidi Zhang

|Oct 06, 2025
KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancers.

Yuedian Ye, Yuanpeng Liao, Yifan Zhang

|May 13, 2024
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.

Haozhe Zhang, Yi Zhou, Yating Feng

Pageof 2

Frequent Collaborators

4 joint publications

Yifan Zhang

3 joint publications

Hailiang Hu

1 joint publications

Zhou Wang

1 joint publications

Shidong Lv